Major Depressive Disorder

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

The drug’s developers respond to the FDA’s decision to deny approval and consider future directions for this indication.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

What is new in research on transcranial magnetic stimulation?

The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.

What is new in research on major depressive disorder?

Psychiatry: a field of medicine that is constantly evolving.

In the largest study of its kind to date, researchers found promising results for subcutaneous ketamine for treatment resistant depression.

A new cognitive biotype for depression may impact symptoms and treatment outcomes.

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, provide their practice pearls for community psychiatrists and psychiatric nurse practitioners who care for patients with major depressive disorder (MDD) to optimize their treatment and management.

Experts provide an overview of novel treatments, including glutamatergic, GABAergic, and psychedelic drugs, that are either approved or currently being evaluated in clinical studies for MDD (major depressive disorders).

From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss the typical strategies for switching therapies for major depressive disorder (MDD).

Practitioners discuss the need to treat patients with major depressive disorder (MDD) to a complete remission vs a decline in symptomology.

The drug has shown statistically significant, clinically meaningful reductions in symptoms of depression, anhedonia.

Did you miss our APA Annual Meeting coverage?

What is the association between the gut microbiome and response to SSRIs in patients with depression?

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss best practices for monitoring and follow-up with patients with major depressive disorder (MDD) to ensure treatment efficacy and safety.

Practitioners discuss their approach to treatment with their patients with major depressive disorder (MDD).

Experts discuss how practitioners are viewing major depressive disorder (MDD) as a chronic condition vs an episodic condition.

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss navigating the challenge of a “one size fits all approach” when treating and identifying the specific needs of patients with major depressive disorder (MDD).

Practitioners discuss the rates of undertreatment in patients suffering from major depressive disorder (MDD).

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, comment on the perception of major depressive disorder (MDD) within the healthcare community and the clinical and practical implications of is this condition.

Fatigue: a very common physical complaint that often accompanies depressive disorders.

From obesity and metabolism in first-episode MDD to psychiatrist liability and suicide, here are highlights from the week in Psychiatric Times.